×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

DiabetesIndia 2022: Nonsteroidal MRAs: A New Hope for Improved Cardiorenal Outcomes in Patients with CKD and T2D

  1037 Views

Dr Shashank Joshi, Mumbai    08 June 2022

  • CKD progression in T2D is driven by the combined effects of metabolic, hemodynamic, inflammatory and fibrotic factors.
  • Inflammation and fibrosis are potential treatment targets to address the residual risk in CKD and T2D.
  • Mineralocorticoid receptor (MR) overactivation is a major driver of kidney damage.
  • MR overactivation, which contributes to inflammation and fibrosis, is a potential treatment target to slow CKD progression.
  • Finerenone, a novel, nonsteroidal, selective MRA, blocks MR overactivation and reduces albuminuria.
  • Finerenone is different from available steroidal MRAs.
  • Finerenone is hypothesized to slow CKD progression and prevent CV events by directly targeting inflammation and fibrosis.
  • FIDELIO-DKD and FIGARO-DKD results indicate that finerenone is an effective investigational treatment option for CV and kidney protection in patients with CKD stage 1-4 and T2D.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.